1,25-Dihydroxyvitamin D₃ inhibits the proliferation of rat mesangial cells induced by high glucose via DDIT4

Da-Peng Chen¹,²,*, Ye-Ping Ma¹,²,*, Li Zhuo², Zheng Zhang¹,², Gu-Ming Zou², Yue Yang², Hong-Mei Gao² and Wen-Ge Li¹,²

¹Graduate School of Peking Union Medical College, Beijing 100730, China
²Department of Nephrology, China-Japan Friendship Hospital, Beijing 100029, China
*These authors share co-first authorship

Correspondence to: Wen-Ge Li, email: wenge_jee2002@126.com

Keywords: diabetic nephropathy; 1,25-Dihydroxyvitamin D₃; proliferation; DDIT4; mTOR

Received: July 31, 2017 Accepted: November 14, 2017 Published: December 09, 2017

ABSTRACT

1,25-Dihydroxyvitamin D₃(1,25(OH)₂D₃) is a secosteroid with antiproliferative property. It also plays a pivotal renoprotective role in diabetic nephropathy. We investigated whether 1,25(OH)₂D₃ could inhibit the proliferation of rat mesangial cells exposed to high glucose via the DNA-damage-inducible transcript 4/mammalian target of rapamycin (DDIT4/mTOR) pathway. The cell proliferation rate and cell cycle duration were measured using cell counting kit-8 assay and flow cytometry. Protein expression was assayed by Western blot. Glucose acted as a growth factor in rat mesangial cells, promoted cell proliferation. In parallel, the protein expression of DDIT4, TSC1/TSC2, and 4E-BP1 were decreased, and Rheb, mTOR, and p70S6K were increased. Acting via the DDIT4/mTOR signaling, 1,25(OH)₂D₃ treatment reversed these pathological changes, upregulated DDIT4, TSC1/TSC2, and 4E-BP1, downregulated Rheb, mTOR, and p70S6K. The short-term overexpression of DDIT4 inhibited the proliferation of rat mesangial cells, similar to 1,25(OH)₂D₃ treatment. siRNA knockdown of DDIT4 suppressed antiproliferative responses to 1,25(OH)₂D₃. These results suggest that 1,25(OH)₂D₃ inhibits the proliferation of rat mesangial cells induced by high glucose via the DDIT4/mTOR signaling pathway.

INTRODUCTION

Diabetic nephropathy (DN) is one of the most common complications of type 1 and type 2 diabetes and the leading cause of end-stage renal disease in the Western world [1]. Proliferation of mesangial cells(MCs) and extracellular matrix(ECM) expansion have been considered as contributing factors to the initial pathophysiologic mechanisms involved in glomerulosclerosis, which is typical of DN [2, 3]. Thus, finding effective approaches to inhibit MCs proliferation is important for preventing glomerulosclerosis in patients with diabetic nephropathy.

1,25-Dihydroxyvitamin D₃ (1,25(OH)₂D₃), the hormonal form of vitamin D, is a member of the secosteroid hormone family whose actions extend far beyond its classic role in calcium homeostasis and bone metabolism. Many studies have demonstrated that 1,25(OH)₂D₃ modulates cell growth and differentiation, including mesangial cells and podocytes [4–7]. The functions of 1,25(OH)₂D₃ are mediated by the interaction of the vitamin D receptor (VDR) with the retinoid X receptor, which binds to specific vitamin D response elements in the promoter region of target genes, resulting in the inhibition of proliferation and the stimulation of differentiation [8].

The serine/threonine kinase mammalian target of rapamycin (mTOR) regulates cell growth, metabolism, and autophagy to maintain cellular homeostasis [9, 10]. The protein kinase mTOR exists in two distinct protein complexes: mTOR complex 1 (mTORC1) and mTORC2. mTORC1 regulates cell growth and proliferation by...
directly phosphorylating two regulators of translation, p70-S6 kinase (p70S6K) and 4E binding protein 1 (4E-BP1) [11]. The mTOR activation plays a pivotal role in the development of DN [12]. Hyperglycemia and its associated growth factors activate mTOR primarily through the phosphatidylinositol 3-kinase/Akt signaling pathway. The induction of mTORC1 by Akt leads to the phosphorylation and thus the inhibition of TSC1/TSC2, thereby stimulating the mTORC1 activator Rheb and leading to downstream effects on protein synthesis and cell proliferation [13, 14]. The role of mTORC2 in regulating cellular processes is not well understood.

The gene encoding DNA-damage-inducible transcript 4 (DDIT4, also known as REDD1) is highly conserved, from Drosophila to humans. The 25 kDa DDIT4 protein is transcriptionally upregulated in response to hypoxia and other cellular insults, including DNA damage, endoplasmic reticulum stress, and energy stress [15, 16]. Recent studies have shown that the binding of 1,25(OH)$_2$D$_3$ to the VDR can increase the expression of DDIT4, which can then activate TSC1/TSC2, thereby inhibiting the expression of mTOR [17–20]. As an essential regulator of mTOR activity, DDIT4 regulates cell growth, apoptosis, and autophagy but have been few studies of its effects on MCs. Therefore, our study examined the effects of 1,25(OH)$_2$D$_3$ on RMCs exposed to high glucose. It also sought to determine whether the effect was mediated by the DDIT4/mTOR signaling pathway.

**RESULTS**

**1,25(OH)$_2$D$_3$ inhibits RMCs proliferation induced by high glucose**

The proliferative activity of RMCs cultured in the presence or absence of 1,25(OH)$_2$D$_3$ was determined using the cell counting kit-8 assay. Cell proliferation was promoted by high glucose and significantly reduced by 1,25(OH)$_2$D$_3$ (Figure 1). There were no significant differences between RMCs treated with 10$^{-9}$ M and 10$^{-7}$ M 1,25(OH)$_2$D$_3$. The optimum response was obtained with 10$^{-7}$ M, which was thus used in subsequent experiments.

**1,25(OH)$_2$D$_3$ regulates the cell-cycle distribution and cell size of RMCs treated with high glucose**

The effects of 1,25(OH)$_2$D$_3$ on the cell-cycle distribution and cell size of RMCs were examined using flow cytometry. High glucose induced a 18.5% decrease in the G0/G1 phase and a 41.9% increase in the S phase, indicating that high glucose promotes cell-cycle progression. Compared with the high-glucose group, 1,25(OH)$_2$D$_3$ markedly extended the G0/G1 phase and reduced the time spent by the cells in the S phase (Figure 2A and Table 1). 1,25(OH)$_2$D$_3$ also decreased the size of RMCs treated with high glucose (Figure 2B and Table 2).

**1,25(OH)$_2$D$_3$ modulates RMCs proliferation induced by high glucose via the DDIT4/mTOR signaling pathway**

To investigate whether the DDIT4/mTOR signaling pathway is involved in regulating the proliferation of RMCs treated with 1,25(OH)$_2$D$_3$, we examined the expression of VDR, DDIT4, TSC1/TSC2, the mTOR mediator Rheb, mTOR, and its downstream proteins 4E-BP1 and p70S6K by Western blot. The protein levels of VDR, DDIT4, TSC1/TSC2, and 4E-BP1 were significantly downregulated ($p < 0.05$) and those of Rheb, mTOR, and p70S6K were significantly upregulated ($p < 0.05$) in the high glucose group vs. the low glucose group. Incubation of RMCs with 1,25(OH)$_2$D$_3$ for 48 h increased VDR expression ($p < 0.05$), restored the expression of TSC1/TSC2 and 4E-BP1, and blocked the aberrant upregulation of Rheb, mTOR and p70S6K (Figure 3). These results suggest that the DDIT4/mTOR signaling pathway plays a key role in 1,25(OH)$_2$D$_3$-modulated RMCs proliferation induced by high glucose.

**Short-term overexpression of DDIT4 suppresses RMCs proliferation via the mTOR signaling pathway**

RMCs were transiently transfected with blank vector or DDIT4 lentiviral vector. The short-term overexpression of DDIT4 suppressed RMCs proliferation and cell-cycle progression (Figure 4A and 4B, Tables 3 and 4). Western blotting showed the significant upregulation of TSC1/TSC2, 4E-BP1 ($p < 0.05$) and downregulation of Rheb, mTOR, and p70S6K ($p < 0.05$) in cells transfected with the DDIT4 vector (Figure 4C). Moreover, the results were similar to those obtained in 1,25(OH)$_2$D$_3$-treated cells.

**siRNA knockdown of DDIT4 suppresses antiproliferative responses to 1,25(OH)$_2$D$_3$**

To determine the functional significance of DDIT4 in mediating RMCs responses to 1,25(OH)$_2$D$_3$, siRNA was used to knock down the expression of DDIT4. DDIT4 mRNA expression was suppressed by 55% in cells exposed to DDIT4-specific siRNA but increased following cotreatment with 1,25(OH)$_2$D$_3$, albeit not significantly ($p > 0.05$). The level of DDIT4 protein was also suppressed in siRNA-treated RMCs ($p < 0.05$), whereas 1,25(OH)$_2$D$_3$ treatment specifically reversed DDIT4-siRNA-induced proliferation and hypertrophy ($p > 0.05$) (Figure 5A and 5B, Tables 5 and 6), restored DDIT4 and TSC1/TSC2 expression, and downregulated Rheb and mTOR expression (Figure 5C).

**DISCUSSION**

The pathogenesis of DM is complicated, the exact pathogenesis remain unclear. Advanced renal glycation
end products [21, 22], the renin-angiotensin system (RAS) activation [23, 24], inflammation [25], and oxidative stress [26] have been shown to involve in DN. Previous studies have shown that vitamin D deficiency is a potential risk factor for diabetic nephropathy [27, 28]. In a randomized controlled trial, paricalcitol, an activated vitamin D analog, significantly reduced albuminuria in patients with diabetic nephropathy [29]. Glomerular basement membrane (GBM) thickening, ECM expansion, and MCs proliferation have long been recognized as pathological hallmark of diabetic nephropathy [3]. However, less is known about the effects of 1,25(OH)₂D₃ on MCs proliferation induced by high glucose and the molecular mechanisms involved in that process.

1,25-Dihydroxyvitamin D₃ is an endocrine hormone with multiple physiological functions, including a pivotal role in immunomodulation and the inhibition of proliferation. [30]. 1,25(OH)₂D₃ inhibited cell proliferation has been reported frequently in oncological studies, but this effect has seldom been shown in DN. Consistent with previous results [31], our in vitro study showed that high glucose promoted the proliferation of RMCs. We also found that cells treated with 1,25(OH)₂D₃ had a significantly

Figure 1: 1,25(OH)₂D₃ inhibits RMCs proliferation induced by high glucose. The proliferative activity of RMCs was detected using a cell counting kit-8 assay. "p < 0.05, HG vs. LG (n = 3); "p < 0.05, HG + VD (10⁻⁶ M) vs. HG (n = 3); "p < 0.05, HG + VD (10⁻⁷ M) vs. HG (n = 3). LG: 5.5 mM glucose; Man: 5.5 mM glucose + 24.5 mM mannitol; HG: 30 mM glucose.

Figure 2: 1,25(OH)₂D₃ regulates the cell-cycle distribution and cell size of RMCs treated with high glucose. The cells were cultured for 48 h in the presence or absence of 1,25(OH)₂D₃. (A) Cell cycle analysis. (B) Cell size. LG: 5.5 mM glucose; Man: 5.5 mM glucose + 24.5 mM mannitol; HG: 30 mM glucose.
Table 1: Cell-cycle distribution of RMCs

| Group | G0/G1 (%) | S (%) | G2/M (%) |
|-------|-----------|-------|----------|
| LG    | 63.6 ± 1.0 | 31.0 ± 0.8 | 5.4 ± 0.6 |
| Man   | 63.2 ± 1.2 | 33.1 ± 1.0 | 3.7 ± 0.4 |
| HG    | 51.8 ± 1.8* | 44.1 ± 1.1* | 4.1 ± 0.5 |
| HG+VD | 62.9 ± 1.7* | 36.3 ± 1.0# | 0.8 ± 0.06# |

LG: 5.5 mM glucose; Man: 5.5 mM glucose + 24.5 mM mannitol; HG: 30 mM glucose.
*p < 0.05, HG vs. LG (n = 3), #p < 0.05, HG+VD vs. HG (n = 3).

Table 2: Cell size of RMCs

| Group | FSC |
|-------|-----|
| LG    | 511 ± 12 |
| Man   | 509 ± 15 |
| HG    | 581 ± 26# |
| HG+VD | 480 ± 25# |

LG: 5.5 mM glucose; Man: 5.5 mM glucose + 24.5 mM mannitol; HG: 30 mM glucose.
*p < 0.05, HG vs. LG (n = 3), #p < 0.05, HG+VD vs. HG (n = 3).

Figure 3: 1,25(OH)_{2}D_{3} modulates RMCs proliferation induced by high glucose via the DDIT4/mTOR signaling pathway. RMCs were cultured for 48 h in the presence or absence of 1,25(OH)_{2}D_{3}. Cell lysates were subjected to Western blot analysis to measure the levels of the indicated proteins. The results are expressed as the relative intensity (adjusted to that of β-actin). *p < 0.05, HG vs. LG (n = 3); #p < 0.05, HG+VD vs. HG (n = 3). LG: 5.5 mM glucose; Man: 5.5 mM glucose + 24.5 mM mannitol; HG: 30 mM glucose.
larger population in the G0/G1 phase and a smaller population in the S phase than cells cultured under high glucose. Thus, 1,25(OH)\(_2\)D\(_3\) could inhibit the proliferation of RMCs exposed to high glucose.

The mTOR activation plays a pivotal role in the development of DN [12, 32]. It has been demonstrated that mTOR regulates cell growth and proliferation by directly phosphorylating two direct downstream targets, p70S6K and 4E-BP1 [11]. Our study showed that the expression of mTOR and p70S6K was elevated in RMCs treated with high glucose. DDIT4 has been shown to inhibit cell growth via regulation of the mTOR signaling pathway.

### Table 3: Cell-cycle distribution of RMCs transfected with DDIT4 vector

| Group            | G0/G1 (%) | S (%)  | G2/M (%) |
|------------------|-----------|--------|----------|
| Blank vector     | 87.1 ± 1.9| 12.6 ± 1.3 | 0.3 ± 0.05 |
| DDIT4 vector     | 81.8 ± 2.1*| 14.5 ± 1.6 | 3.7 ± 1.0* |

*\(p < 0.05\), DDIT4 vector vs. blank vector (\(n = 3\)).

### Table 4: Size of RMCs transfected with DDIT4 vector

| Group            | FSC       |
|------------------|-----------|
| Blank vector     | 444 ± 12  |
| DDIT4 vector     | 406 ± 14* |

*\(p < 0.05\), DDIT4 vector vs. blank vector (\(n = 3\)).

Figure 4: The short-term overexpression of DDIT4 suppresses RMCs proliferation and cell-cycle progression via the mTOR signaling pathway. RMCs were transiently transfected with blank vector or DDIT4 lentiviral vector. (A) The proliferative activity of the transfected RMCs was detected using the cell counting kit-8 assay. *\(p < 0.05\), DDIT4 vector vs. blank vector (\(n = 3\)). (B) Analysis of the cell-cycle distribution and size of the transfected RMCs by flow cytometry. (C) DDIT4, TSC1/TSC2, Rheb, mTOR, 4E-BP1, and p70S6K protein expression levels were detected by Western blot.*\(p < 0.05\), DDIT4 vector vs. blank vector (\(n = 3\)).
signaling pathway upstream of the TSC1-TSC2 complex [17]. Lisse et al. [18] found that DDIT4 could act as a direct target of 1,25(OH)₂D₃ in the suppression of cell proliferation in response to vitamin D treatment in osteoblasts. Yang et al. reported that high glucose could inhibit the expression of DDIT4 whereas expression is restored by 1,25(OH)₂D₃ treatment in β-cells [19]. Recently Wang et al. reported that in vitro and in vivo 1,25(OH)₂D₃ can effectively inhibit mesangial cells proliferation via the DDIT4/TSC2/mTOR pathway [20]. As predicted, the elevated expression of DDIT4 induced by 1,25(OH)₂D₃ was observed in the present study. Moreover, we found that the elevated expression of DDIT4 led to an increase in the expression of TSC1/TSC2, which result in the inhibition of mTOR expression. We provided evidence that 1,25(OH)₂D₃ by directly promoting DDIT4 expression, regulated RMCs proliferation via the mTOR signaling pathway.

**Figure 5:** siRNA knockdown of the DDIT4 antiproliferative responses to 1,25(OH)₂D₃. RMCs were transfected with negative control siRNA orDDIT4-specific siRNA in the presence or absence of 1,25(OH)₂D₃. (A) The proliferative activity of the transfected RMCs was detected using the cell counting kit-8 assay. *p < 0.05, DDIT4 siRNA vs. control (n = 3). (B) Cell-cycle distribution and size of the transfected RMCs analyzed using flow cytometry. (C) DDIT4, TSC1/TSC2, Rheb, mTOR, 4E-BP1 and p70S6K protein expression levels were detected by Western blot. *p < 0.05, DDIT4 siRNA vs. control; †p < 0.05, DDIT4 siRNA+VD vs. DDIT4 siRNA (n = 3).
To obtain further evidence that 1,25(OH)\(_2\)D\(_3\) regulates the mTOR signaling pathway via DDIT4, RMCs were transfected with blank vector or DDIT4 lentiviral vector. The short-term overexpression of DDIT4 inhibited the proliferation of RMCs. In the transfected cells, the level of DDIT4 protein was significantly upregulated whereas the levels of mTOR and the downstream protein p70S6K were downregulated, similar to the effects observed following 1,25(OH)\(_2\)D\(_3\) treatment.

siRNA (small interfering RNA) is able to regulate the expression of genes, by a phenomenon known as RNA interference [33]. siRNA has gained attention as a potential therapeutic reagent due to its ability to inhibit specific genes in many genetic diseases. It also can be used as tools to study single gene function both in vivo and in vitro [34]. RMCs were transfected with DDIT4-specific siRNA. siRNA knockdown of DDIT4 suppressed the antiproliferative responses of RMCs to 1,25(OH)\(_2\)D\(_3\) and extinguished the expression of mTOR, p70S6K, and 4E-BP1.

Taken together, our work provided strong evidence that in vitro 1,25(OH)\(_2\)D\(_3\) can inhibit the proliferation of RMCs induced by high glucose, by suppressing the mTOR signaling pathway, which is mediated by DDIT4 activation. In order to further clarify, our team will study further in animals.

**MATERIALS AND METHODS**

**Reagents**

Crystalline 1,25(OH)\(_2\)D\(_3\) (Sigma, St. Louis, MO, USA) was reconstituted in ethanol. 1,25(OH)\(_2\)D\(_3\) was added to the incubation medium to produce final medium concentrations ranging from 10\(^{-7}\) to 10\(^{-6}\) M.

**Cell culture and transfection**

RMCs were obtained from the American Type Culture Collection (ATCC) and grown in RPMI-1640 medium containing 10% fetal bovine serum (FBS), 100 U penicillin/ml and 100 µg streptomycin/ml in a 5% CO\(_2\) incubator at 37°C. Trypsin (0.25%) was used for cell passages. The cells were first synchronized in serum-free RPMI-1640 medium for 24 h, which was then replaced with DMEM containing 10% FBS and 5.5 mM glucose (low-glucose medium), DMEM containing 10% FBS, 5.5 mM glucose and 24.5 mM mannitol (mannitol medium), or DMEM containing 10% FBS and 30 mM glucose (high-glucose medium). Then all of the cells were cultured in the presence or absence of 1,25(OH)\(_2\)D\(_3\). RMCs were transfected with the DDIT4 lentiviral vector (Applied Biological Materials Inc., Richmond, BC, Canada) or blank vector (Applied Biological Materials, Inc.) using Lipofectamine LTX and the Plus™ reagent (Invitrogen, Carlsbad, CA, USA). RMCs were transfected with DDIT4-specific siRNA (Applied Biological Materials, Inc.) or negative control siRNA (Applied Biological Materials, Inc.) using jetPRIME™ (Polyplus Transfection, Illkirch, France). The treated cells were assessed by cell counting kit-8 assay, flow cytometry, and Western blot.

**Cell proliferation assay**

Cell proliferation was measured using the CCK-8 assay. RMCs were seeded in 96-well plates (4 × 10\(^3\) cells/well), synchronized by incubation in serum-free medium for 24 h, and then incubated with the test compounds as described above. After 24, 48, and 72 h, 10 µL CCK-8 reagent (Dojindo, Japan) was added to each well. The cells were cultured for 1 h, after which the optical density (OD) was measured at 450 nm using a microplate reader (Biotek, Winooski, VT, USA). The arithmetic mean OD of six wells per group was calculated.

**Flow cytometry**

Cell-cycle analysis was performed using flow cytometry. RMCs were synchronized by incubation in
serum-free medium for 24 h and then incubated with the test compounds for 48 h as described above. Then the cells were washed twice with cold phosphate-buffered saline (PBS) and fixed with 75% alcohol for 24 h at 4°C. The fixed cells were collected by centrifugation, washed with PBS, stained for 30 min at room temperature using the Coulter DNA prep reagent kit (Beckman Coulter, Inc., Brea, CA, USA), and finally analyzed using a Beckman Coulter FC 500 (Beckman Coulter, Inc.) together with the CXP software (Beckman Coulter, Inc.).

Western blot

Proteins were extracted from RMCs using RIPA lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% deoxycholate, 1% Nonidet P-40, 0.1% SDS, 1 mM PMSF, and protease cocktail at 1 μg/mL). Protein concentrations were determined using a BCA kit (Thermo Scientific, Rockford, AL, USA). Equal amounts of protein (60 μg) were separated by SDS-PAGE on a 6%, 10%, or 12% acrylamide gel and then transferred onto a nitrocellulose membrane. After the membrane had been blocked with non-fat dry milk in Tris-buffered saline containing 0.05% Tween 20 for 1 h at room temperature, it was probed with the following primary antibodies overnight at 4°C: anti-VDR (catalogue no.: ab109234, Abcam, USA), anti-DDIT4 (catalogue no.: NB51–77321, Novus Biologicals, USA), anti-TSC1 (catalogue no.: 6935S, Cell Signaling Technology, USA), anti-TSC2 (catalogue no.: 4308P, Cell Signaling Technology), anti-Rheb (catalogue no.: 13879S, Cell Signaling Technology), anti-mTOR (catalogue no.: Ab51044, Abcam), anti-4E-BP1 (catalogue no.: ab2606, Abcam), and anti-p70S6K (catalogue no.: ab32359, Abcam). After extensive washing, the membranes were incubated with Dylight anti-rabbit IgG secondary antibody. The antigens were visualized using the Odyssey infrared imaging system (LI-COR Biotechnology, Nebraska, USA). The results were expressed as the relative intensity (RI) intensity (adjusted to that of β-actin) of each band.

Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR)

Total RNAs were isolated using TRIzol reagent (Invitrogen, USA). Total RNA (2 μg) was reverse-transcribed to obtain the cDNA using a Transcript first-strand cDNA synthesis SuperMix kit (TransGen Biotech, Beijing, China) according to the manufacturer’s instructions. Real-time PCR was performed in an Applied Biosystems 7500 real-time PCR system using a SYBR Select master mix kit (Applied Biosystems, Foster City, CA, USA). The PCR primers are shown in Table 7. The PCR conditions for all genes were as follows: initial denaturation at 95°C for 10 min followed by 40 cycles of denaturation at 95°C for 30 s; annealing at 59°C for 30 s; and extension at 72°C for 30 s. The relative RNA levels were calculated using the ΔΔCt method [35].

Statistical analyses

The results are expressed as the mean ± SD. Statistical analyses were performed using the SPSS 20.0 software package (SPSS, Inc., USA). Statistical comparisons between multiple groups were performed using a one-way ANOVA, applying the Bonferroni method to control for multiple testing. A p value < 0.05 was considered to indicate statistical significance.

ACKNOWLEDGMENTS AND FUNDING

This work was supported by the National Natural Science Foundation of China (81170675, 81200537), and Beijing Municipal Science and Technology Project (D131100004713002, D171100002817003). And also support by The foundation of State Key Laboratory of Kidney Disease (Grant Number 2011DAV00088).

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest in this work.

REFERENCES

1. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014; 64:510–533.
2. Steffes MW, Østerby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes. 1989; 38, 1077–1081.
3. Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol. 2011; 6:395–423.

4. Yang J, Ikekoe T, Nishioka C, Ni L, Koeffler HP, Yokoyama A. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of AML cells in vitro and in vivo. Exp Hematol. 2010; 38:666–676.

5. Li R, Lou Y, Zhang W, Dong Q, Han B. Vitamin D inhibition of lung adenocarcinoma cell proliferation in vitro. Tumour Biol. 2014; 35:10953–10958.

6. Wang Y, Deb DK, Zhang Z, Sun T, Liu W, Yoon D, Kong J, Chen Y, Chang A, Li YC. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol. 2012; 23:1977–1986.

7. Panichi V, Migliori M, Taccola D, Filippi C, De Nisco L, Giovannini L, Palla R, Tetta C, Camussi G. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int. 2001; 60:87–95.

8. Kim S, Shevde NK, Pike JW. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts. J Bone Miner Res. 2005; 20:305–317.

9. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature. 2013; 497:217–223.

10. Wang S, Livingston MJ, Su Y, Dong Z. Reciprocal regulation of cilia and autophagy via the mTOR and proteasome pathways. Autophagy. 2015; 11:607–616.

11. Hardie DG. Signal transduction: How cells sense energy. Nature. 2011; 472:176–177.

12. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol. 2003; 14:S254–258.

13. Zhuo L, Liu D, Duan Y, Liu F, Deng H. 1,25(OH)2D3 protects β cell against high glucose-induced apoptosis through mTOR suppressing. Mol Cell Endocrinol. 2015; 414:111–119.

14. Wang H, Wang J, Qu H, Wei H, Ji B, Yang Z, Wu J, He Q, Luo Y, Liu D, Duan Y, Liu F, Deng H. In vitro and in vivo inhibition of mTOR by 1,25-dihydroxyvitamin D3 to improve early diabetic nephropathy via the DDIT4/TSC2/mTOR pathway. Endocrine. 2016; 54:348–359.

15. Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol. 2003; 14:S254–258.

16. Yamagishi S, Matsu T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev. 2010; 3:101–108.

17. Ellisen LW. Growth control under stress: mTOR regulation through the REDD1-TSC pathway. Cell Cycle. 2005; 4:1500–1502.

18. Lisse TS, Liu T, Irmler M, Beckers J, Chen H, Adams JS, Hewison M. Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. FASEB J. 2011; 25:937–947.

19. Yang Z, Liu F, Qu H, Wang H, Xiao X, Deng H. 1,25(OH)2D3 protects β cell against high glucose-induced apoptosis through mTOR suppressing. Mol Cell Endocrinol. 2015; 414:111–119.

20. Wang H, Wang J, Qu H, Wei H, Ji B, Yang Z, Wu J, He Q, Luo Y, Liu D, Duan Y, Liu F, Deng H. In vitro and in vivo inhibition of mTOR by 1,25-dihydroxyvitamin D3 to improve early diabetic nephropathy via the DDIT4/TSC2/mTOR pathway. Endocrine. 2016; 54:348–359.

21. Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol. 2003; 14:S254–258.

22. Yamagishi S, Matsu T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev. 2010; 3:101–108.

23. Yacoub R, Campbell KN. Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renovasc Dis. 2015; 8:29–40.

24. Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egidio J. Therapeutic approaches to diabetic nephropathy--beyond the RAS. Nat Rev Nephrol. 2014; 10:325–346.

25. Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci. 2013; 124:139–152.

26. Singh DK, Winocour P, Farrington K. Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol. 2011; 7:176–184.

27. Usluogullari CA, Balkan F, Caner S, Ucier R, Kaya C, Erozy R, Cakir B. The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitus. BMC Endocr Disord. 2015; 15:33.

28. Xiao X, Wang Y, Hou Y, Han F, Ren J, Hu Z. Vitamin D deficiency and related risk factors in patients with diabetic nephropathy. J Int Med Res. 2016; 44:673–684.

29. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Prickett Y, Remuzzi G, Ritz E, Andress D. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010; 376: 1543-1551.

30. Plum LA, DeLuca HF. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov. 2010; 9:941–955.

31. Gao J, Wang F, Wang W, Su Z, Guo C, Cao S. Emodin suppresses hyperglycemia-induced proliferation and fibronectin expression in mesangial cells via inhibiting cFLIP. PLoS One. 2014; 9:e93588.

32. Mori H, Inoki K, Masutani K, Wakabayashi Y, Komai K, Nakagawa R, Guan KL, Yoshimura A. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin...
has a strong therapeutic potential. Biochem Biophys Res Commun. 2009; 384:471–475.

33. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136:642–655.

34. Lam JK, Chow MY, Zhang Y, Leung SW. siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids. 2015; 4:e252.

35. Chen D, Li Y, Mei Y, Geng W, Yang J, Hong Q, Feng Z, Cai G, Zhu H, Shi S, Bai XY, Chen X. miR-34a regulates mesangial cell proliferation via the PDGFR-β/Ras-MAPK signaling pathway. Cell Mol Life Sci. 2014; 71:4027–4042.